This news article on a talk at the American Association of Clinical Endocrinologists 2017 Conference surprised me.
Fewer than one in five hypogonadal men are adherent to prescribed topical testosterone, new research indicates. The findings, from a large commercial insurance database, were presented May 5 here at the American Association of Clinical Endocrinologists (AACE) 2017 Annual Scientific & Clinical Congress by Michael Grabner, PhD, of HealthCore, Wilmingon, Delaware. Among a total of 3184 men with primary or secondary hypogonadism who had filled a prescription for topical testosterone therapy of any kind (brand-name or generic), just 17% were defined as adherent. And over 1 year, 81% of the men discontinued treatment.
Fewer than one in five hypogonadal men are adherent to prescribed topical testosterone, new research indicates. The findings, from a large commercial insurance database, were presented May 5 here at the American Association of Clinical Endocrinologists (AACE) 2017 Annual Scientific & Clinical Congress by Michael Grabner, PhD, of HealthCore, Wilmingon, Delaware. Among a total of 3184 men with primary or secondary hypogonadism who had filled a prescription for topical testosterone therapy of any kind (brand-name or generic), just 17% were defined as adherent. And over 1 year, 81% of the men discontinued treatment.
